Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study

In postmenopausal Japanese women with osteoporosis, romosozumab treatment resulted in large and significant gains in BMD from baseline and compared with placebo. Romosozumab 210 mg QM showed the largest gains in BMD and was generally well tolerated. The efficacy and safety of romosozumab 210 mg QM in this phase 2 study of postmenopausal women with osteoporosis were similar to those in an international phase 2 study.